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Renal Cell Carcinoma (RCC) constitutes 80 to 85% of primary 
renal neoplasms. At presentation, up to 25% of patients with  
RCC will have evidence of metastases or locally advanced 
disease. [1] Patients will rarely present with any symptoms since 
the majority of patients are incidentally diagnosed due to 
radiologic procedures performed for other indications. The 
classic triad of RCC (flank pain, hematuria, and a palpable 
abdominal renal mass) is only seen in 9% of patients, and when 
present, is strongly suggestive of locally advanced disease. [2, 
3] The highest rates of RCC are seen in the Czech Republic and 
North America. [4] In North America, the incidence of RCC is 
63,000 new cases, and approximately 14,000 people die from 
RCC each year. [5] RCC is the 6th most common cancer in men and 
the 8th most common cancer in women in the United States. [6] 
RCC is 50 % more common in males with the average age of 
diagnosis being 64. [7-10] Risk factors for RCC include smoking, 
hypertension, obesity, renal cystic disease, occupational 
exposures, and genetic factors. [11] Of these, obesity and smoking 
are the most consistent. Factors that have been reported to 
reduce the risk of RCC development include moderate 
alcohol, fruit, vegetable, and fatty fish consumption. [12] 
Several subtypes of RCC have been identified, with clear cell 
carcinoma being the most common, accounting for 75 to 85% of 
tumors. This subtype typically has a deletion of chromosome 
3p25 and arises from the proximal tubule. [13] Macroscopically, 
the tumor may have solid or cystic features. A more favorable 
prognosis has been associated with the rare multilocular variant 
in comparison to the presence of a sarcomatoid pattern, which 
carries an overall poor prognosis. Clear cell carcinoma can occur 
sporadically but also has a strong genetic association with von 
Hippel-Lindau disease. [11]  
Other subtypes of RCC include papillary or chromophilic (10-15 
%), chromophobe (5-10 %), oncocytic (3-7 %) and collecting 
duct carcinoma (Bellini’s duct) (very rare). RCC is considered the 
most lethal of urologic cancers because a patient without 
intervention who has stage IV metastatic disease has a 5-year 
survival rate of 23% in comparison to 96% for stage I disease.[14] 
 
History and Physical Background 
Operative Approach 
1. Once informed consent was obtained, the patient was placed 
in a 60° modified flank position. 
2. After creating pneumoperitoneum, a  
12-mm port was inserted at the lateral  
border of the rectus  abdominus muscle  
across from the 12th rib. The rest of the  
ports were inserted under direct vision as shown above. 
3. The liver was released as much as possible and retracted. 
4. In order to visualize the inferior vena cava and the renal vein, 
the duodenum was kocherized medially. Dissection was 
proceeded cranially to the right adrenal vein, which was 
subsequently clipped and resected. 
5. Once the adrenal vein was excised, the adrenal gland was 
circumferentially mobilized. Arterial blood supply was 
controlled using a vessel sealer. 
6. The adrenal gland was removed and sent to pathology. 
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History of Present Illness: The patient is a 73-year-old 
Caucasian male presenting with an asymptomatic right adrenal 
mass. 
• Initially presented to the emergency department on 9/6/15 
for abdominal pain and a small bowel obstruction 
• Incidentally found out that he had a right adrenal gland mass 
Past Medical and Surgical History: In 2007, he had an episode 
of abdominal pain. A CT scan showed a 12 cm lesion on the left 
kidney (Figure 1). 
• Past Medical History: Hypertension, Atrial fibrillation, 
Hypothyroidism, Chronic kidney disease, and Memory loss 
• Past Surgical History:  Open cholecystectomy (1981), Left 
Open Radical Nephrectomy and Left Adrenalectomy was 
performed via midline incision (2007), and Ventral wall 
hernia repair with mesh (2009) 
• 12 cm tumor, confined within the renal capsule, and it 
invaded the renal vein (negative margins) 
• Pathology revealed renal cell carcinoma, clear cell subtype 
 
Labs and Images: CT scan without contrast from the initial 
emergency department visit incidentally showed a 3.1 cm low-
density right adrenal nodule indicative of a lipid rich 
adenoma in addition to a right lung lower lobe 8 mm rounded 
nodule that was nonspecific and present on previous imaging  
Repeat CT scan with contrast done on 10/7/15 showed a 2.9 x 
2.4 cm enhancing lesion involving the right adrenal gland 
most consistent with metastatic disease (Figure 2) and a 8 mm 
nodule in the right lower lobe, which was suspected to be 
metastatic disease 
CT guided core biopsy done on 12/30/15 revealed metastatic 
renal cell carcinoma 
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Discussion 
FIGURE 3: This is a  
cross section of the  
gross specimen sent  
to pathology. The  
adrenal gland  
mostly comprised 
of tumor. 
FIGURE 4: This is a  
sectioned sample  
showing the tumor  
next to the small  
remainder of healthy  
adrenal tissue still  
present. 
FIGURE 2: 3.1 cm lesion found in the right 
adrenal gland in 2015. Note that the left 
kidney is absent. 
The patient was under routine surveillance after the removal of 
the left kidney in 2007, with no evidence of metastatic disease 
on imaging until his RCC recurrence in 2015.  
RCC has several treatment options. The standard of care for 
localized RCC is surgical resection. Since our patient has 
metastatic disease, adjuvant therapy is the ideal treatment 
method. This includes surgical resection prior to chemotherapy 
or immunotherapy. Current focus is on therapeutics that target 
vascular endothelial growth factor receptor (VEGF-R) and 
mammalian target of rapamycin (mTOR). [15] Since this patient 
presented with a solitary metastatic RCC lesion, the treatment of 
choice is surgical resection if feasible.  With 
adrenalectomy(solitary metastatic lesion), the patient’s 5-year 
survival rate at is estimated to be 51%, whereas the 5-year 
survival rate with adjuvant targeted therapy is estimated to be 
18%. [16]  Current research indicates that there is no 
improvement in survival outcome with adjuvant therapy after 
resection of a solitary metastatic RCC lesion. [15] 
This patient had a medical oncologist, urologist, and 
endocrinologist who prepped the patient for adrenalectomy by 
starting preoperative steroids.  He was counselled on long term 
steroid replacement therapy.  He was consented for a right 
robotic adrenalectomy with possible conversion to open if 
necessary.   
Figure 5 
Family History: 1st degree relative with prostate cancer 
Social History: Patient denies tobacco and recreational drug 
use 
Physical Exam: Patient had a midline abdominal scar from his 
nephrectomy and a right upper quadrant abdominal scar from 
his cholecystectomy 
• Vital signs were stable 
• Review of Symptoms was noncontributory. 
2015 
FIGURE 1:  12 cm tumor replacing the entire 
left kidney in 2007. No evidence of metastatic 
disease.   
2007 
